CHN1 is a Novel Prognostic Marker for Diffuse Large B-Cell Lymphoma

References

• Swerdlow SH, Campo E, Pileri SA, et al. The 2016 revision of the World Health Organization classification of lymphoid neoplasms. Blood. 2016;127(20):2375–2390. doi:10.1182/blood-2016-01-643569
   PubMed Web of Science ®Google Scholar
• Zhang J, Grubor V, Love CL, et al. Genetic heterogeneity of diffuse large B-cell lymphoma. Proc Natl Acad Sci U S A. 2013;110(4):1398–1403. doi:10.1073/pnas.1205299110
   PubMed Web of Science ®Google Scholar
• Wang Y, Farooq U, Link BK, et al. Late relapses in patients with diffuse large B-cell lymphoma treated with immunochemotherapy. J Clin Oncol. 2019;37(21):1819–1827. doi:10.1200/JCO.19.00014
   PubMed Web of Science ®Google Scholar
• Tanimura A, Hirai R, Nakamura M, Takeshita M, Hagiwara S, Miwa A. The prognostic impact of dose-attenuated R-CHOP therapy for elderly patients with diffuse large B-cell Lymphoma. Intern Med. 2018;57(24):3521–3528. doi:10.2169/internalmedicine.0990-18
   PubMed Web of Science ®Google Scholar
• International Non-Hodgkin’s Lymphoma Prognostic Factors P. A predictive model for aggressive non-Hodgkin’s lymphoma. N Engl J Med. 1993;329(14):987–994. doi:10.1056/NEJM199309303291402
   PubMed Web of Science ®Google Scholar
• Vallet N, Ertault M, Delaye JB, et al. Hypercalcemia is associated with a poor prognosis in lymphoma a retrospective monocentric matched-control study and extensive review of published reported cases. Ann Hematol. 2020;99(2):229–239. doi:10.1007/s00277-019-03890-w
   Web of Science ®Google Scholar
• Sehn LH, Scott DW, Chhanabhai M, et al. Impact of concordant and discordant bone marrow involvement on outcome in diffuse large B-cell lymphoma treated with R-CHOP. J Clin Oncol. 2011;29(11):1452–1457. doi:10.1200/JCO.2010.33.3419
   PubMed Web of Science ®Google Scholar
• Alizadeh AA, Eisen MB, Davis RE, et al. Distinct types of diffuse large B-cell lymphoma identified by gene expression profiling. Nature. 2000;403(6769):503–511. doi:10.1038/35000501
   PubMed Web of Science ®Google Scholar
• Scott DW, Mottok A, Ennishi D, et al. Prognostic significance of diffuse large b-cell lymphoma cell of origin determined by digital gene expression in formalin-fixed paraffin-embedded tissue biopsies. J Clin Oncol. 2015;33(26):2848–2856. doi:10.1200/JCO.2014.60.2383
   PubMed Web of Science ®Google Scholar
• Chapuy B, Stewart C, Dunford AJ, et al. Molecular subtypes of diffuse large B cell lymphoma are associated with distinct pathogenic mechanisms and outcomes. Nat Med. 2018;24(5):679–690. doi:10.1038/s41591-018-0016-8
   PubMed Web of Science ®Google Scholar
• Schmitz R, Wright GW, Huang DW, et al. Genetics and Pathogenesis of Diffuse Large B-Cell Lymphoma. N Engl J Med. 2018;378(15):1396–1407. doi:10.1056/NEJMoa1801445
   PubMed Web of Science ®Google Scholar
• Wright GW, Huang DW, Phelan JD, et al. A probabilistic classification tool for genetic subtypes of diffuse large B cell lymphoma with therapeutic implications. Cancer Cell. 2020;37(4):551–568 e514. doi:10.1016/j.ccell.2020.03.015
   PubMed Web of Science ®Google Scholar
• Al-Tourah AJ, Gill KK, Chhanabhai M, et al. Population-based analysis of incidence and outcome of transformed non-Hodgkin’s lymphoma. J Clin Oncol. 2008;26(32):5165–5169. doi:10.1200/JCO.2008.16.0283
   PubMed Web of Science ®Google Scholar
• Bastion Y, Sebban C, Berger F, et al. Incidence, predictive factors, and outcome of lymphoma transformation in follicular lymphoma patients. J Clin Oncol. 1997;15(4):1587–1594. doi:10.1200/JCO.1997.15.4.1587
   PubMed Web of Science ®Google Scholar
• Link BK, Maurer MJ, Nowakowski GS, et al. Rates and outcomes of follicular lymphoma transformation in the immunochemotherapy era: a report from the University of Iowa/mayoclinic specialized program of research excellence molecular epidemiology resource. J Clin Oncol. 2013;31(26):3272–3278. doi:10.1200/JCO.2012.48.3990
   PubMed Web of Science ®Google Scholar
• Montoto S, Davies AJ, Matthews J, et al. Risk and clinical implications of transformation of follicular lymphoma to diffuse large B-cell lymphoma. J Clin Oncol. 2007;25(17):2426–2433. doi:10.1200/JCO.2006.09.3260
   PubMed Web of Science ®Google Scholar
• Sarkozy C, Trneny M, Xerri L, et al. Risk factors and outcomes for patients with follicular lymphoma who had histologic transformation after response to first-line immunochemotherapy in the PRIMA trial. J Clin Oncol. 2016;34(22):2575–2582. doi:10.1200/JCO.2015.65.7163
   PubMed Web of Science ®Google Scholar
• Wagner-Johnston ND, Link BK, Byrtek M, et al. Outcomes of transformed follicular lymphoma in the modern era: a report from the National LymphoCare Study (NLCS). Blood. 2015;126(7):851–857. doi:10.1182/blood-2015-01-621375
   PubMed Web of Science ®Google Scholar
• Gao Y, Sun B, Hu J, et al. Identification of gene modules associated with survival of diffuse large B-cell lymphoma treated with CHOP-based chemotherapy. Pharmacogenomics J. 2020;20(5):705–716. doi:10.1038/s41397-020-0161-6
   Web of Science ®Google Scholar
• Guo D, Wang H, Sun L, et al. Identification of key gene modules and hub genes of human mantle cell lymphoma by coexpression network analysis. PeerJ. 2020;8:e8843. doi:10.7717/peerj.8843
   PubMed Web of Science ®Google Scholar
• Zhang Y, Luo Y, Qin SL, et al. The clinical impact of ICOS signal in colorectal cancer patients. Oncoimmunology. 2016;5(5):e1141857. doi:10.1080/2162402X.2016.1141857
   PubMed Web of Science ®Google Scholar
• Artemaki PI, Sklirou AD, Kontos CK, et al. High clusterin (CLU) mRNA expression levels in tumors of colorectal cancer patients predict a poor prognostic outcome. Clin Biochem. 2020;75:62–69. doi:10.1016/j.clinbiochem.2019.10.008
   Web of Science ®Google Scholar
• Yang GF, Li XM, Xie D. Overexpression of clusterin in ovarian cancer is correlated with impaired survival. Int J Gynecol Cancer. 2009;19(8):1342–1346. doi:10.1111/IGC.0b013e3181a83ed9
   PubMed Web of Science ®Google Scholar
• Hazzaa SM, Elashry OM, Afifi IK. Clusterin as a diagnostic and prognostic marker for transitional cell carcinoma of the bladder. Pathol Oncol Res. 2010;16(1):101–109. doi:10.1007/s12253-009-9196-3
   PubMed Web of Science ®Google Scholar
• Gyorffy B, Bottai G, Fleischer T, et al. Aberrant DNA methylation impacts gene expression and prognosis in breast cancer subtypes. Int J Cancer. 2016;138(1):87–97. doi:10.1002/ijc.29684
   PubMed Web of Science ®Google Scholar
• Zhang S, Zhang D, Zhu Y, Guo H, Zhao X, Sun B. Clusterin expression and univariate analysis of overall survival in human breast cancer. Technol Cancer Res Treat. 2006;5(6):573–578. doi:10.1177/153303460600500604
   Web of Science ®Google Scholar
• Watari H, Kanuma T, Ohta Y, et al. Clusterin expression inversely correlates with chemosensitivity and predicts poor survival in patients with locally advanced cervical cancer treated with cisplatin-based neoadjuvant chemotherapy and radical hysterectomy. Pathol Oncol Res. 2010;16(3):345–352. doi:10.1007/s12253-009-9235-0
   Web of Science ®Google Scholar
• Albert JM, Gonzalez A, Massion PP, et al. Cytoplasmic clusterin expression is associated with longer survival in patients with resected non small cell lung cancer. Cancer Epidemiol Biomarkers Prev. 2007;16(9):1845–1851. doi:10.1158/1055-9965.EPI-07-0146
   Web of Science ®Google Scholar
• Braud VM, Biton J, Becht E, et al. Expression of LLT1 and its receptor CD161 in lung cancer is associated with better clinical outcome. Oncoimmunology. 2018;7(5):e1423184. doi:10.1080/2162402X.2017.1423184
   PubMed Web of Science ®Google Scholar
• Gentles AJ, Newman AM, Liu CL, et al. The prognostic landscape of genes and infiltrating immune cells across human cancers. Nat Med. 2015;21(8):938–945. doi:10.1038/nm.3909
   PubMed Web of Science ®Google Scholar
• Liu X, Wu S, Yang Y, Zhao M, Zhu G, Hou Z. The prognostic landscape of tumor-infiltrating immune cell and immunomodulators in lung cancer. Biomed Pharmacother. 2017;95:55–61. doi:10.1016/j.biopha.2017.08.003
   PubMed Web of Science ®Google Scholar
• Ramezani S, Shirdel A, Rafatpanah H, et al. Assessment of HTLV-1 proviral load, LAT, BIM, c-FOS and RAD51 gene expression in adult T cell leukemia/lymphoma. Med Microbiol Immunol. 2017;206(4):327–335. doi:10.1007/s00430-017-0506-1
   PubMed Web of Science ®Google Scholar
• Gilles SR, Yohe SL, Linden MA, Dolan M, Hirsch B, Grzywacz B. CD161 is expressed in a subset of T-cell prolymphocytic leukemia cases and is useful for disease follow-up. Am J Clin Pathol. 2019;152(4):471–478. doi:10.1093/ajcp/aqz060
   Web of Science ®Google Scholar
• Nascimento AF, Pinkus JL, Pinkus GS. Clusterin, a marker for anaplastic large cell lymphoma immunohistochemical profile in hematopoietic and nonhematopoietic malignant neoplasms. Am J Clin Pathol. 2004;121(5):709–717. doi:10.1309/GQ2RLNDWLB9WY6UU
   Web of Science ®Google Scholar
• Le KS, Thibult ML, Just-Landi S, et al. Follicular B lymphomas generate regulatory T cells via the ICOS/ICOSL pathway and are susceptible to treatment by anti-ICOS/ICOSL Therapy. Cancer Res. 2016;76(16):4648–4660. doi:10.1158/0008-5472.CAN-15-0589
   PubMed Web of Science ®Google Scholar
• Kanderova V, Kuzilkova D, Stuchly J, et al. High-resolution Antibody Array Analysis of Childhood Acute Leukemia Cells. Mol Cell Proteomics. 2016;15(4):1246–1261. doi:10.1074/mcp.M115.054593
   Web of Science ®Google Scholar
• Evans JC, Frayling TM, Ellard S, Gutowski NJ. Confirmation of linkage of Duane’s syndrome and refinement of the disease locus to an 8.8-cM interval on chromosome 2q31. Hum Genet. 2000;106(6):636–638. doi:10.1007/s004390000311
   PubMed Web of Science ®Google Scholar
• Appukuttan B, Gillanders E, Juo SH, et al. Localization of a gene for Duane retraction syndrome to chromosome 2q31. Am J Hum Genet. 1999;65(6):1639–1646. doi:10.1086/302656
   PubMed Web of Science ®Google Scholar
• Engle EC, Andrews C, Law K, Demer JL. Two pedigrees segregating Duane’s retraction syndrome as a dominant trait map to the DURS2 genetic locus. Invest Ophthalmol Vis Sci. 2007;48(1):189–193. doi:10.1167/iovs.06-0631
   PubMed Web of Science ®Google Scholar
• Clark C, Austen O, Poparic I, Guthrie S. alpha2-Chimaerin regulates a key axon guidance transition during development of the oculomotor projection. J Neurosci. 2013;33(42):16540–16551. doi:10.1523/JNEUROSCI.1869-13.2013
   Web of Science ®Google Scholar
• Miyake N, Demer JL, Shaaban S, et al. Expansion of the CHN1 strabismus phenotype. Invest Ophthalmol Vis Sci. 2011;52(9):6321–6328. doi:10.1167/iovs.11-7950
   PubMed Web of Science ®Google Scholar
• Miyake N, Chilton J, Psatha M, et al. Human CHN1 mutations hyperactivate alpha2-chimaerin and cause Duane’s retraction syndrome. Science. 2008;321(5890):839–843. doi:10.1126/science.1156121
   PubMed Web of Science ®Google Scholar
• Couch G, Redman JE, Wernisch L, et al. The discovery and validation of biomarkers for the diagnosis of esophageal squamous dysplasia and squamous cell carcinoma. Cancer Prev Res. 2016;9(7):558–566. doi:10.1158/1940-6207.CAPR-15-0379
   Web of Science ®Google Scholar
• Miyazaki K, Yamaguchi M, Imai H, et al. Gene expression profiling of diffuse large B-Cell lymphomas supervised by CD5 expression. Int J Hematol. 2015;102(2):188–194. doi:10.1007/s12185-015-1812-2
   PubMed Web of Science ®Google Scholar
• Testoni M, Zucca E, Young KH, Bertoni F. Genetic lesions in diffuse large B-cell lymphomas. Ann Oncol. 2015;26(6):1069–1080. doi:10.1093/annonc/mdv019
   PubMed Web of Science ®Google Scholar
• Pfeifer M, Grau M, Lenze D, et al. PTEN loss defines a PI3K/AKT pathway-dependent germinal center subtype of diffuse large B-cell lymphoma. Proc Natl Acad Sci U S A. 2013;110(30):12420–12425. doi:10.1073/pnas.1305656110
   PubMed Web of Science ®Google Scholar
• Wahlin BE, Sander B, Christensson B, Kimby E. CD8+ T-cell content in diagnostic lymph nodes measured by flow cytometry is a predictor of survival in follicular lymphoma. Clin Cancer Res. 2007;13(2 Pt 1):388–397. doi:10.1158/1078-0432.CCR-06-1734
   Web of Science ®Google Scholar
• Xu-Monette ZY, Xiao M, Au Q, et al. Immune profiling and quantitative analysis decipher the clinical role of immune-checkpoint expression in the tumor immune microenvironment of DLBCL. Cancer Immunol Res. 2019;7(4):644–657. doi:10.1158/2326-6066.CIR-18-0439
   PubMed Web of Science ®Google Scholar
• Dave SS, Wright G, Tan B, et al. Prediction of survival in follicular lymphoma based on molecular features of tumor-infiltrating immune cells. N Engl J Med. 2004;351(21):2159–2169. doi:10.1056/NEJMoa041869
   PubMed Web of Science ®Google Scholar
• Noyori O, Komohara Y, Nasser H, et al. Expression of IL-34 correlates with macrophage infiltration and prognosis of diffuse large B-cell lymphoma. Clin Transl Immunol. 2019;8(8):e1074. doi:10.1002/cti2.1074
   Web of Science ®Google Scholar
• Marchesi F, Cirillo M, Bianchi A, et al. High density of CD68+/CD163+ tumour-associated macrophages (M2-TAM) at diagnosis is significantly correlated to unfavorable prognostic factors and to poor clinical outcomes in patients with diffuse large B-cell lymphoma. Hematol Oncol. 2015;33(2):110–112. doi:10.1002/hon.2142
   PubMed Web of Science ®Google Scholar
• Cai QC, Liao H, Lin SX, et al. High expression of tumor-infiltrating macrophages correlates with poor prognosis in patients with diffuse large B-cell lymphoma. Med Oncol. 2012;29(4):2317–2322. doi:10.1007/s12032-011-0123-6
   Web of Science ®Google Scholar
• Wang J, Gao K, Lei W, et al. Lymphocyte-to-monocyte ratio is associated with prognosis of diffuse large B-cell lymphoma: correlation with CD163 positive M2 type tumor-associated macrophages, not PD-1 positive tumor-infiltrating lymphocytes. Oncotarget. 2017;8(3):5414–5425. doi:10.18632/oncotarget.14289
   PubMedGoogle Scholar